![zio patch heart monitor zio patch heart monitor](https://img.deusm.com/informationweek/2015/12/1323544/7-Zio-XT-Patch.jpg)
“Fortunately, monitoring has proven effective both pre- and post-procedure in quickly detecting these complications.” Tarakji, MD, Principal Investigator for the Brady-TAVR study at Cleveland Clinic's Heart, Vascular & Thoracic Institute. “Bradyarrhythmias are a common occurrence post-TAVR and can create major complications in patients who have undergone the procedure,'' said Khaldoun G. The study found that bradyarrhythmias can be detected with 14-day cardiac monitoring through Zio XT before and after TAVR. Guidelines from the Journal of the American College of Cardiology (JACC) recommend that ECG monitoring be conducted pre- and post- TAVR, given the clinical importance of monitoring patients undergoing this procedure. The study aimed to determine the prevalence of bradyarrhythmias among patients undergoing transcatheter aortic valve replacement (TAVR) and whether pre- and post-TAVR extended rhythm monitoring with Zio XT would aid in the prediction of conduction disturbances and permanent pacemaker (PPM) implantation risk.
![zio patch heart monitor zio patch heart monitor](https://cdn.shopify.com/s/files/1/0057/5166/8849/products/Zio_300x300.png)
In addition, the results of the Brady-TAVR study, titled “Bradyarrhythmias detected by extended rhythm recording in patients undergoing transcatheter aortic valve replacement,” were published in Heart Rhythm Journal in November 2021. Zio XT was associated with significantly higher documentation 1 of AF/AFL -related supraventricular tachycardias and non-sustained ventricular tachycardia than both 24-hour Holter and 30-day event monitoring. It was designed to assess diagnostic yield, outcomes, and resource utilization by monitoring modality in individuals without previously documented AF or AFL. The KP-Rhythm2 study examined the efficacy of Zio XT, Holter monitors, and event monitors. “This latest clinical research further validates that monitoring with Zio by iRhythm leads to better diagnostic yield and aids in more accurate diagnoses.” “It’s been demonstrated that Holter monitors often result in repeat testing, longer time to diagnosis, increased costs of healthcare, and a delay to clinical intervention,” said iRhythm CEO Quentin Blackford. a 30-day event monitor yielding similar diagnostic yield for atrial fibrillation (AF)/ atrial flutter (AFL) ≥30 seconds in a general population of adults without known prior AF/AFL. While earlier peer-reviewed studies have found Zio XT to be better than Holter and event monitors in the detection of arrhythmias, the KP-Rhythm2 study, led by Kaiser Permanente and supported by a research grant from iRhythm Technologies, Inc., is the first study to address specifically Zio XT patch vs. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, announced that the results of the KP-Rhythm2 study, titled “Diagnostic yield, outcomes and resource utilization with different ambulatory electrocardiographic monitoring strategies,” were published in the American Journal of Cardiology (AJC). 28, 2022 (GLOBE NEWSWIRE) - iRhythm Technologies, Inc.